NRAS and JIA at NRAS welcome NICE decision

22 October 2015

NICE have today released the FAD giving wider access to Abatacept, adalimumab, etanercept and tocilizumab for the treatment of juvenile idiopathic arthritis. The National Rheumatoid Arthritis Society (JIA@NRAS) warmly welcomes this determination.

Ailsa Bosworth, CEO of NRAS said: “We are delighted and this represents an important development for families living with JIA. It will provide them with greater options when a child or young person doesn’t respond to standard treatment. Children and young people with JIA can have their quality of life significantly reduced and JIA can often interrupt attendance at school and reduce participation in activities such as sport. We hope that this guidance will lead to better care and improved outcomes for children and young people living with the condition.”

Anne Gilbert, JIA Youth and Family Services Manager at NRAS said: “This is great news for families affected by JIA. JIA can severely impact the ability of children and young people to interact socially with their peers and enjoy normal family life.”